Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas, with generally poor prognosis. Historically, there has been a lack of consensus regarding appropriate therapeutic measures for the disease, with conventional frontline chemotherapies being ut...
Main Authors: | Annabelle L. Rodd, Katherine Ververis, Tom C. Karagiannis |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-01-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.4137/CMO.S8536 |
Similar Items
-
Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
by: Tom C. Karagiannis, et al.
Published: (2012-08-01) -
Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
by: Koichi Kitazume, et al.
Published: (2019-07-01) -
Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
by: Casanova M, et al.
Published: (2011-10-01) -
Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial
by: Seonyoung Park, et al.
Published: (2020-11-01) -
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
by: Bodiford A, et al.
Published: (2014-10-01)